Please assess the completion status of the following clinical trial:

Trial Title: CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age \& histologic diagnosis of adenocarcinoma of the prostate~* Completed surgery or radiation at least 8 weeks prior to entry with removal of all visible disease~* Clinical Stage D0 prostate cancer with rising PSA and PSA \>2ng/ml.~* ECOG performance of \<2~* Normal hematologic, renal and liver function~Exclusion Criteria:~* Cannot have evidence of immunosuppression or have been treated with immunosuppressive therapy.~* No prior treatment with an LHRH agonist or nonsteroidal antiandrogen such as casodex or flutamide~* No evidence for metastatic disease per bone scan or CT scan of the abdomen and pelvis~* No prior treatment with anti-CTLA 4 monoclonal antibody~* No history of known autoimmune disorder or HIV, hepatitis B or hepatitis C~* No known brain metastases~* No history of inflammatory bowel conditions including diverticulitis, ulcerative colitis, etc.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Bicalutamide 150mg orally days 1-28 followed by CP-675,206 IV on day 29. Cycle is repeated once at month 3

Based on this trial design, predict the completion outcome and termination type (if applicable).